A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
This study is a Phase III, double-masked, multicenter, randomized, sham injection-controlled study evaluating the efficacy and safety of lampalizumab administered by intravitreal injections in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Inclusion Criteria:
Exclusion Criteria:
Ocular Exclusion Criteria: Study Eye
CABA, 1023, Argentina
Göttingen, 37075, Germany
Lübeck, 23538, Germany
Debrecem, 4032, Hungary
Rome, Lazio 00198, Italy
Milan, Lombardy 20100, Italy
Krakow, 31-501, Poland
L'Hospitalet de Llobregat, Barcelona 8907, Spain
San Cugat Del Valles, Barcelona 08195, Spain